Free daily and weekly newsletters covering biopharma headlines and breaking news, read by 200,000+ industry leaders. CLS members get $100 off unlimited access with an Insider subscription: code CLS100.
Endpoints News covers what actually moves a program forward: trial readouts, FDA decisions, financings, M&A and the policy shifts behind them, from NIH funding to drug pricing. We break stories the rest of the industry follows, and we explain what they mean for the people running programs, raising capital and setting strategy.
An Insider subscription removes the paywall on everything we publish. CLS members get $100 off with code CLS100*. Get your Insider subscription.
Not ready to subscribe? Start free with the Main Edition, our daily rundown of the top biopharma news and analysis, delivered every business day at 11:30 a.m. ET. Sign up today.
Have a team? Enterprise subscriptions give unlimited access to your whole organization. Contact [email protected] for a quote, and mention you are a CLS member.
About Endpoints News
Endpoints News, part of FT Specialist at the Financial Times, is where the biopharma and healthcare industries go for up-to-the-moment news, in-depth reporting on the science and the business, and coverage of the people, companies and money that drive innovation. Independent since 2016, beholden to no one.
Endpoints readers are the people who need to know everything happening in biotech and pharma: executives, drug developers, business development leaders, investors and regulators. More than 200,000 specialists get an Endpoints newsletter every day, including at every major pharmaceutical manufacturer and at hundreds of biotech companies, startups and service providers.
CLS Member Benefits
CLS members receive $100 off an Endpoints News Insider subscription with code CLS100, plus discounted group pricing on Enterprise subscriptions for teams.
*Insider discount only applicable to new subscribers.